74. Khader S.A., Pearl J.E., Sakamoto K., et al: IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 2005; 175:788-795.


412. Teo S.S.S., Shingadia D.V.: Does BCG have a role in tuberculosis control and prevention in the United Kingdom?. Arch Dis Child 2006; 91:529-531.


DIFTERIJA:


detection of toxigenic Corynebacterium diphtheriae strains isolated during the Russian
methods for detection of diphtheria toxin among isolates of pathogenic corynebacteria. J Clin
62. Nakao H., Popovic T.: Development of a direct PCR assay for detection of the diphtheria
diphtheriae and Corynebacterium ulcerans by a novel real-time PCR. J Clin Microbiol 2008;
46:2822-2823.
64. Sing A, Berger A, Schneider-Brachert W, et al. Rapid detection and molecular
differentiation of toxigenic Corynebacterium diphtheriae and Corynebacterium ulcerans
Corynebacterium diphtheriae from northwestern Russia and surrounding countries studied by
tox, and its regulatory element, dxtR, in Corynebacterium diphtheriae strains causing
71. Nakao H., Popovic T.: Development of a rapid ribotyping method for Corynebacterium
diphtheriae by using PCR single-strand conformation polymorphism: comparison with
37:1092-1099.
75. Marston C.K., Jamieson F., Cahoon F., et al: Persistence of a distinct Corynebacterium
diphtheriae clonal group within two communities in the United States and Canada where
76. Farizo K.M., Strebel P.M., Chen R.T., et al: Fatal respiratory disease due to
Corynebacterium diphtheriae: case report and review of guidelines for management,
78. Galazka A.M., Robertson S.E.: Diphtheria: changing patterns in the developing world and


214. Schmitt-Grohé S., Stehr K., Cherry J.D.Pertussis Vaccine Study Group, et al: Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. Dev Biol Stand 1997; 89:113-118.


TETANUS


100. Abel J.J., Firor W.M., Chalain W.: Researches on tetanus, IX: further evidence to show that tetanus toxin is not carried to central nervous system by way of the axis cylinders of motor nerves. Bull Johns Hopkins Hosp 1938; 63:373-403.


204. Attygalle D., Rodrigo N.: Magnesium sulphate for control of spasms in severe tetanus: can we avoid sedation and artificial ventilation?. Anaesthesia 1997; 52:956-962.


546. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months-Advisory Committee on Immunization Practices (ACIP). MMWR2011. 60, 1424–1426


611. Zurrer G., Steffen R.: Side effects in tetanus vs. diphtheria tetanus vaccination in travellers. 1988.Zurich, Switzerland; April 5–8, Abstract WPO3.3


689. Committee on Trauma, American College of Surgeons: Prophylaxis against tetanus in wound management (revised 1995). accessed April 5


HRIPAVAC

97. Bronne-Shanbury C., Miller D., Standfast A.F.: The serotypes of Bordetella pertussis isolated in Great Britain between 1941 and 1968 and a comparison with the serotypes observed in other countries over this period. J Hyg (Lond) 1976; 76:265-275.


115. Weber C., Bouraux-Eude C., Coralie G., et al: Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 2001; 39:4396-4403.


293. Centers for Disease Control and Prevention: Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months: Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1424-1426.
293a. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011 Oct 21;60.


446. Gustafsson L., Hallander H., Olin P.: Efficacy Trial of acellular pertussis vaccines: technical report trial I, with results of preplanned analysis of safety, efficacy and


554. National Institute of Allergy and Infectious Diseases. Pertussis vaccine in healthy pregnant women.
555. Dalhousie University. Pertussis maternal immunization study.
556. Gall S.A., Myers J., Pichichero M.: Maternal immunization with tetanus-diphtheria-
pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet
Gynecol 2011; 204:334.e1-334.e5.
557. Population and Public Health Branch, Centre for Infectious Disease Prevention and
Control: Canada Immunization Guide. 6th ed. Ottawa (Ontario), Canada, National Advisory
Committee on Immunization, 2002.
558. World Health Organization. WHO vaccine preventable diseases monitoring system.
33:997-1003.
to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for

DJEČJA PARALIZA

1. Poliomyelitis Vaccine Evaluation Center: Evaluation of 1954 field trials of poliomyelitis
2. Poliomyelitis Vaccine Evaluation Center: Evaluation of 1954 field trials of poliomyelitis
3. Poliomyelitis Vaccine Evaluation Center: Evaluation of 1954 field trials of poliomyelitis
4. Poliomyelitis Vaccine Evaluation Center: Evaluation of 1954 field trials of poliomyelitis
Health 1955; 45:49-51.
7. Landsteiner K., Popper E.: Ueberstragung der poliomyelitis acuta auf affen. Z
8. Bodian D., Morgan I., Howe H.: Differentiation of types of poliomyelitis viruses; the
grouping of fourteen strains into three basic immunologic types. Am J Hyg 1949; 49:234-
245.
2004; 1:3-5.


142. Sutter R. Personal communication.


237. Danjou G., Silier T., Dupuy M.: Comparison of DTaP-IPV vaccine with DTP-IPV (Tetracoq) vaccine administered as a second booster at 4 to 7 years of age. 1997.


327. Dove A.W., Racaniello V.R.: The polio eradication effort: should vaccine eradication be next?. Science 1997; 277:779-780.[see comments]
336. Kimman T.Y., Book N.: The polio eradication effort has been a great success—let's finish it and replace it with something even better. Lancet Infect Dis 2006; 6(10):675-678.

HAEMOPHILUS INFLUENZAE TIPA B


336. Pichichero M.E., Passador S.: Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine

HEPATITIS B


14. Beeson P.: Jaundice occurring one to four months after transfusion of blood or plasma: report of seven cases. JAMA 1943; 121:1332-1334.


OSPICE

148. Deer B.: How the case against the MMR vaccine was fixed. BMJ 2011; 342:77-82.
154. Siegel M.: Congenital malformations following chickenpox, measles, mumps, and
156. Siegel M., Fuerst H.T., Peress N.S.: Comparative fetal mortality in maternal virus
diseases: a prospective study on rubella, measles, mumps, chicken pox, and hepatitis. N Engl
157. Stokes Jr J., Maris E.P., Gellis S.S.: Chemical, clinical and immunologic studies on the
products of human plasma fractionation. XI. The use of concentrated normal human serum
gamma globulin (human immune serum globulin) in the prevention and attenuation of
158. Janeway C.A.: Use of concentrated human serum γ-globulin in the prevention and
159. Brody J.A., Bridenbraugh E.: Prophylactic γ-globulin and live measles vaccine in an
103:682-687.
164. Schaffner W., Schluederberg A.E.S., Byrne E.B.: Clinical epidemiology of sporadic
166. Linnemann C.C., Hegg M.E., Rotte T.C., et al: Measles IgM response during reinfection
vaccine failure during sustained outbreak in a highly vaccinated population. JAMA 1990;
263:2467-2471.
live measles vaccine: 15 years of observation in Zhejiang Province, China. Bull World Health


418. Potency test. Code of Federal Regulations Title 21, Sec. 630.34. April 1, 1996


730. Deer B.: How the case against the MMR vaccine was fixed. BMJ 2011; 342:c5347.
matriculation requirements on risk for measles outbreaks. JAMA 1994; 255:1127-1132.
745. Yip F.Y., Papania M.J., Redd S.B.: Measles outbreak epidemiology in the United States,
748. Subbarao E.K., Amin S., Kumar M.L.: Prevaccination serologic screening for measles in
749. Grabowsky M., Markowitz L.: Serologic screening, mass immunization and implications
28 June 2012.)
immunodeficiency virus infected children: a retrospective survey. Pediatrics 1988; 82:229-
233.
751. Centers for Disease Control and Prevention (CDC) : Recommendations of the Advisory
Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in
complications among hematopoietic cell transplantation recipients: a global perspective. Biol
practices following allogenic bone marrow transplantation. JAMA 1997; 277:1148-1151.
transplantation; influence of donor type, graft type, intensity of conditioning and graft-versus-
host disease. Bone Marrow Transplant 2004; 34:589-593.
28 June 2012 at
758. Centers for Disease Control and Prevention (CDC) : Guidelines for preventing
opportunistic infections among hematopoietic stem cell transplant recipients.
Recommendations of the CDC, the Infectious Diseases Society of America, and the American
760. Starr S., Berkovich S.: The effect of measles, gamma globulin modified measles, and
attenuated measles vaccine on the course of treated tuberculosis in children. Pediatrics 1965;
35:97-102.
severe combined immunodeficiency: report of a case [abstract]. Presented at the Annual
Meeting of Laboratory Investigation, 1992.
762. Moss W.J., Cutts F., Griffin D.E.: Implications of the human immunodeficiency virus


865. www.measlesinitiative.org

ZAUŠNJACI


528. Zhou F., Reef S., Massoudi M., et al: An economic analysis of the current universal 2-
189(supp1):S131-S145.
529. Ciofi Degli Atti M.L., Rota M.C., Bella A.: Do changes in policy affect vaccine coverage
levels? Results of a national study to evaluate childhood vaccination coverage and reasons for
530. Eradication of measles, rubella and routine mumps in Cuba: report of a technical
533. Schmid D., Holzmann H., Alfery C.: Mumps outbreak in young adults following a
festival in Austria, 2006. Euro Surveill  2008; 13(7):
measures. Euro Surveill  2010; 15(23):
537. Jones A.G., White J.M., Begg N.T.: The impact of MMR vaccine on mumps infection in
538. Vaccination coverage statistics for children up to two years of age in the United
539. Donaghy M., Cameron J.C., Friederichs V.: Increasing incidence of mumps in Scotland:
330:1132-1135.
541. Health Protection Agency. Confirmed Cases of Measles, Mumps and Rubella 1996–
2009. 2011
340:c696.doi:10.1136/bmj.c696
544. Hendrickson B.A., Turner J.R.: MMR vaccination, ileal lymphoid nodular hyperplasia,
288:3155-3158.
measles, mumps, and rubella vaccine: a systematic review of current epidemiological
547. DeStefano F., Thompson W.W.: MMR vaccine and autism: an update of the scientific
548. Mrozek-Budzyn D., Kieltyka A., Majewksa R.: Lack of association between measles-
mumps-rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J
2010; 29:397-400.


573. Centers for Disease Control and Prevention: Mumps outbreaks on university campuses: Illinois, Wisconsin, South Dakota. MMWR 1987; 36:496.495


RUBELA


442. Schell K., Kenny M.T., Jackson J.E.: Serological evaluation of measles virus (Schwarz strain), mumps virus (Jeryl Lynn strain) and rubella virus (Cendehill strain) combination vaccines. J Biol Stand 1975; 3:231-239.


RAZNO:


